Inflammopharmacology
Leading citation impact metric from Clarivate Journal Citation Reports
45 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 3.00đ | WoS Q1 có IF ≥ 5.0(IF: 6.3) | 🔵 Computed |
| 2025 | 3.00đ | WoS Q1 có IF ≥ 5.0(IF: 5.3) | 🔵 Computed |
| 2024 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.6) | 🔵 Computed |
| 2023 | 3.00đ | WoS Q1 có IF ≥ 5.0(IF: 5.8) | 🔵 Computed |
| 2022 | 3.00đ | WoS Q1 có IF ≥ 5.0(IF: 5.093) | 🔵 Computed |
| 2021 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.473) | 🔵 Computed |
| 2020 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.238) | 🔵 Computed |
| 2019 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.838) | 🔵 Computed |
| 2018 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.304) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
IMMUNOLOGY | JCRSCIE | 34/183 | Q1 |
TOXICOLOGY | JCRSCIE | 11/106 | Q1 |
IMMUNOLOGY | JCISCIE | 36/183 | Q1 |
TOXICOLOGY | JCISCIE | 16/106 | Q1 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 320 | 193 |
| 2025 | 5.3 | 458 | 2,446 |
| 2024 | 4.6 | 220 | 2,594 |
| 2023 | 5.8 | 273 | 5,234 |
| 2022 | 5.093 | 221 | 5,024 |
| 2021 | 4.473 | 114 | 3,222 |
| 2020 | 3.238 | 97 | 4,228 |
| 2019 | 3.838 | 125 | 4,593 |
| 2018 | 3.304 | 114 | 3,609 |
| 2017 | — | 129 | 5,364 |
| 2016 | — | 47 | 1,885 |
| 2015 | — | 30 | 1,592 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Inflammopharmacology
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics